C4 Therapeutics Q1 2026 net loss $25.1M; cash $268.3M; new Roche DAC collaboration

C4 Therapeutics, Inc.

2026-Q1 EPS reported -$0.20 revenue$6,152,000

Revenue $6.2M (down from $7.2M YoY); net loss $25.1M ($0.20 EPS) vs $26.3M ($0.37 EPS).
Cash $268.3M at March 31, 2026; runway to end of 2028.
Decision to not advance CFT8919 (EGFR L858R degrader) outside Greater China.
New collaboration with Roche for degrader-antibody conjugates; $20M upfront payment received.
Cemsidomide Phase 2 MOMENTUM trial enrollment on track; Phase 1b with elranatamab first patient dosed.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

C4 Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $6.2 million, net income $25.1 million.

Period: first quarter ended March 31, 2026
Revenue: $6.2 million
Net income: $25.1 million
Result: reported results

Exact text from the filing

Global Healthcare Conference taking place in Miami, FL from June 8 - 10, 2026. FIRST QUARTER 2026 FINANCIAL RESULTS Revenue: Total revenue for the first quarter of 2026 was $6.2 million, compared to $7.2 million for the first quarter of 2025. The decrease in revenue resulted from the conclusion of the research collaboration with Merck and the prioritization of

View on SEC.gov

572 earnings releases filed in the last 30 days. Browse all earnings releases →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-033861

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.